Literature DB >> 19816874

Usefulness of brain natriuretic peptide level at implant in predicting mortality in patients with advanced but stable heart failure receiving cardiac resynchronization therapy.

Aiman El-Saed1, Andrew Voigt, Alaa Shalaby.   

Abstract

BACKGROUND: Brain natriuretic peptide (BNP) level has emerged as a predictor of death and hospital readmission in patients with heart failure (HF). The value of baseline BNP assessment in advanced HF patients receiving cardiac resynchronization defibrillator therapy (CRT-D) has not been firmly established. HYPOTHESIS: We hypothesized that a baseline BNP level would predict all cause mortality and HF hospitalization in HF patients receiving cardiac resynchronization therapy.
METHODS: A retrospective chart review of all patients having BNP assessment prior to implantation of a CRT-D for standard indications during 2004 and 2005 was conducted at the Veterans Affairs Pittsburgh Healthcare System. The primary endpoint was all-cause mortality and the secondary endpoint was HF-related hospitalization. We used findings from the receiver operating characteristic (ROC) curve to define low (<492 pg/mL) and high (> or =492 pg/mL) BNP groups.
RESULTS: Out of 173 CRT-D recipients, 115 patients (mean age 67.0 +/- 10.7 years, New York Heart Association [NYHA] class 2.9 +/- 0.3, left ventricular ejection fraction [LVEF] 22.5% +/- 9.6%, QRS 148.3 +/- 30.4 ms) had preimplantation BNP measured (mean 559 +/- 761 pg/mL and median 315 pg/mL). During a mean follow-up time of 17.5 +/- 6.5 mo, 27 deaths (23.5%) and 31 HF hospitalizations (27.0%) were recorded. Compared to those with low BNP (n = 74), those of high BNP (n = 41) were older, had lower LVEF, higher creatinine levels, suffered more deaths, and HF hospitalizations. In multivariate regression models, higher BNP remained a significant predictor of both the primary endpoint (hazard ratio [HR]: 2.89, 95% confidence interval [CI] 1.06-7.88, p = 0.038) and secondary endpoint (HR: 4.23, 95% CI: 1.68-10.60, p = 0.002).
CONCLUSIONS: Baseline BNP independently predicted mortality and HF hospitalization in a predominantly older white male population of advanced HF patients receiving CRT-D. Elevated BNP levels may identify a vulnerable HF population with a particularly poor prognosis despite CRT-D.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19816874      PMCID: PMC6653145          DOI: 10.1002/clc.20490

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  8 in total

Review 1.  Sex differences in device therapy for heart failure: utilization, outcomes, and adverse events.

Authors:  Naomi D Herz; Joseph Engeda; Robbert Zusterzeel; William E Sanders; Kathryn M O'Callaghan; David G Strauss; Samantha B Jacobs; Kimberly A Selzman; Ileana L Piña; Daniel A Caños
Journal:  J Womens Health (Larchmt)       Date:  2015-03-20       Impact factor: 2.681

2.  Association of BNP and Troponin Levels with Outcome among Cardiac Resynchronization Therapy Recipients.

Authors:  Alaa A Shalaby; William T Abraham; Gregg C Fonarow; Malcolm M Bersohn; John Gorcsan; Li-Yin Lee; Jasmina Halilovic; Samir Saba; Alan Maisel; Jagmeet P Singh; Ali Sonel; Alan Kadish
Journal:  Pacing Clin Electrophysiol       Date:  2015-03-30       Impact factor: 1.976

3.  The role of B-type natriuretic Peptide testing in guiding outpatient heart failure treatment.

Authors:  Noreen P Kelly; James L Januzzi
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

4.  Sex-specific mortality differences in heart failure patients with ischemia receiving cardiac resynchronization therapy.

Authors:  Zhonglin Han; Zheng Chen; Rongfang Lan; Wencheng Di; Xiaohong Li; Hongsong Yu; Wenqing Ji; Xinlin Zhang; Biao Xu; Wei Xu
Journal:  PLoS One       Date:  2017-07-06       Impact factor: 3.240

5.  Brain natriuretic peptide (BNP) may play a major role in risk stratification based on cerebral oxygen saturation by near-infrared spectroscopy in patients undergoing major cardiovascular surgery.

Authors:  Hiroshi Mukaida; Masakazu Hayashida; Satoshi Matsushita; Makiko Yamamoto; Atsushi Nakamura; Atsushi Amano
Journal:  PLoS One       Date:  2017-07-12       Impact factor: 3.240

Review 6.  Sex Differences in Implantation and Outcomes of Cardiac Resynchronization Therapy in Real-World Settings: A Systematic Review of Cohort Studies.

Authors:  Omar Dewidar; Haben Dawit; Victoria Barbeau; David Birnie; Vivian Welch; George A Wells
Journal:  CJC Open       Date:  2021-09-09

7.  Prognostic Value of Natriuretic Peptides for All-Cause Mortality, Right Ventricular Failure, Major Adverse Events, and Myocardial Recovery in Advanced Heart Failure Patients Receiving a Left Ventricular Assist Device: A Systematic Review.

Authors:  Eva Janssen; J Wouter Jukema; Saskia L M A Beeres; Martin J Schalij; Laurens F Tops
Journal:  Front Cardiovasc Med       Date:  2021-07-07

Review 8.  Do optimal prognostic thresholds in continuous physiological variables really exist? Analysis of origin of apparent thresholds, with systematic review for peak oxygen consumption, ejection fraction and BNP.

Authors:  Alberto Giannoni; Resham Baruah; Tora Leong; Michaela B Rehman; Luigi Emilio Pastormerlo; Frank E Harrell; Andrew J S Coats; Darrel P Francis
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.